{"protocolSection": {"identificationModule": {"nctId": "NCT01481779", "orgStudyIdInfo": {"id": "12146"}, "secondaryIdInfos": [{"id": "I2R-MC-BIAN", "type": "OTHER", "domain": "Eli Lilly and Company"}, {"id": "2011-001261-40", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Eli Lilly and Company", "class": "INDUSTRY"}, "briefTitle": "A Study in Participants With Type 1 Diabetes Mellitus", "officialTitle": "The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study", "acronym": "IMAGINE 1"}, "statusModule": {"statusVerifiedDate": "2018-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-01"}, "primaryCompletionDateStruct": {"date": "2013-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-11-28", "studyFirstSubmitQcDate": "2011-11-28", "studyFirstPostDateStruct": {"date": "2011-11-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-03-16", "resultsFirstSubmitQcDate": "2018-03-16", "resultsFirstPostDateStruct": {"date": "2018-04-17", "type": "ACTUAL"}, "dispFirstSubmitDate": "2014-04-25", "dispFirstSubmitQcDate": "2014-04-25", "dispFirstPostDateStruct": {"date": "2014-05-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-03-16", "lastUpdatePostDateStruct": {"date": "2018-04-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Eli Lilly and Company", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is:\n\n* To compare the blood sugar control of LY2605541 with insulin glargine after 78 weeks of treatment.\n* To compare the rate of night-time low blood sugar episodes on LY2605541 with insulin glargine during 78 weeks of treatment.\n* To compare the number of participants on LY2605541 reaching blood sugar targets without low blood sugar episodes at night to those taking insulin glargine after 78 weeks of treatment.\n* To compare the rate of hypoglycemia episodes on LY2605541 with insulin glargine during 78 weeks of treatment."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 1"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 455, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LY2605541 + Insulin Lispro", "type": "EXPERIMENTAL", "description": "LY2605541 titrated based on blood glucose readings, administered by subcutaneous (SC) injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.", "interventionNames": ["Drug: LY2605541", "Drug: Insulin Lispro"]}, {"label": "Glargine + Insulin Lispro", "type": "ACTIVE_COMPARATOR", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.", "interventionNames": ["Drug: Glargine", "Drug: Insulin Lispro"]}], "interventions": [{"type": "DRUG", "name": "Glargine", "description": "Administered by SC injection via a pen device.", "armGroupLabels": ["Glargine + Insulin Lispro"]}, {"type": "DRUG", "name": "LY2605541", "description": "Administered by SC injection with a pen device.", "armGroupLabels": ["LY2605541 + Insulin Lispro"]}, {"type": "DRUG", "name": "Insulin Lispro", "description": "Administered by SC injection with a pen device.", "armGroupLabels": ["Glargine + Insulin Lispro", "LY2605541 + Insulin Lispro"], "otherNames": ["LY275585", "Humalog"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Hemoglobin A1c (HbA1c) at 26 Weeks", "description": "HbA1c is a test that measures a participant's average blood glucose level over a 2- to 3-month timeframe. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM), adjusting for treatment, stratification factors (baseline low-density lipoprotein cholesterol \\[LDL-C\\] \\[\\<100 milligrams per deciliter (mg/dL) and \u2265100 mg/dL\\] and country), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.", "timeFrame": "26 weeks"}], "secondaryOutcomes": [{"measure": "Hemoglobin A1c (HbA1c)", "description": "HbA1c is a test that measures a participant's average blood glucose level over a 2- to 3-month timeframe. LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline LDL-C \\[\\<100 mg/dL and \u2265100 mg/dL\\] and country), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects.", "timeFrame": "52 weeks and 78 weeks"}, {"measure": "Change From Baseline in Hemoglobin A1c (HbA1c)", "description": "HbA1c is a test that measures a participant's average blood glucose level over a 2- to 3-month timeframe. LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline LDL-C \\[\\<100 mg/dL and \u2265100 mg/dL\\] and country), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects.", "timeFrame": "Baseline, 26 weeks, 52 weeks, 78 weeks"}, {"measure": "Percentage of Participants With Hemoglobin A1c (HbA1c) Less Than 7.0% or Less Than or Equal to 6.5% Using Last Observation Carried Forward (LOCF)", "description": "HbA1c is a test that measures a participant's average blood glucose level over a 2- to 3-month timeframe. The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, then multiplying by 100.", "timeFrame": "26 weeks and 52 weeks and 78 weeks"}, {"measure": "Proportion of Participants With Hemoglobin A1c (HbA1c) Less Than 7.0% Without Nocturnal Hypoglycemia", "description": "Hypoglycemic episodes are defined as an event that is associated with reported signs and symptoms of hypoglycemia and/or a documented blood glucose concentration of \u226470 mg/dL (3.9 millimoles per liter \\[mmol/L\\]). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. The percentage of participants was calculated by dividing the number of participants with HbA1c \\<7.0% without nocturnal hypoglycemia by the total number of participants analyzed, then multiplying by 100.", "timeFrame": "26 weeks and 52 weeks and 78 weeks"}, {"measure": "Total Hypoglycemia Rates (Adjusted by 30 Days)", "description": "Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of \u226470 mg/dL (3.9 mmol/L). Group mean rates of total hypoglycemia (per 30 days) are presented and were calculated from negative binomial regression models (number of episodes = treatment + baseline total hypoglycemia rate, with log \\[exposure in days/30\\] as an offset variable). Group mean is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.", "timeFrame": "Baseline through 26 weeks and Baseline through 52 weeks and Baseline through 78 weeks"}, {"measure": "Percentage of Participants With Total Hypoglycemia Events", "description": "Hypoglycemic events are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented BG concentrations of \u226470 mg/dL (3.9 mmol/L). The percentage of participants was calculated by dividing the number of participants with hypoglycemic episodes by the total number of participants analyzed, then multiplying by 100.", "timeFrame": "Baseline through 26 weeks and Baseline through 52 weeks and Baseline through 78 weeks"}, {"measure": "Nocturnal Hypoglycemia Rates (Adjusted by 30 Days)", "description": "Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or a documented BG concentration of \u226470 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. Group mean rates of nocturnal hypoglycemia (per 30 days) are presented and were calculated from negative binomial regression models (number of episodes = treatment + baseline nocturnal hypoglycemia rate, with log \\[exposure in days/30\\] as an offset variable). Group mean is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.", "timeFrame": "Baseline through 26 weeks and Baseline through 52 weeks and Baseline through 78 weeks"}, {"measure": "Percentage of Participants With Nocturnal Hypoglycemic Events", "description": "Hypoglycemic episodes are defined as an event that is associated with reported signs and symptoms of hypoglycemia and/or a BG concentration of \u226470 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. The percentage of participants was calculated by dividing the number of participants with nocturnal hypoglycemic episodes by the total number of participants analyzed, then multiplying by 100.", "timeFrame": "Baseline through 26 weeks and Baseline through 52 weeks and Baseline through 78 weeks"}, {"measure": "Fasting Serum Glucose (FSG) by Laboratory Measurement", "description": "LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], baseline LDL-C level \\[\\<100 mg/dL and \u2265100 mg/dL\\], and country), visit, treatment-by-visit interaction, and corresponding baseline dependent variable as the fixed effects, and participants as the random effect.", "timeFrame": "26 weeks and 52 weeks and 78 weeks"}, {"measure": "Fasting Blood Glucose (FBG) Intra-participant Variability", "description": "FBG was measured by self-monitored blood glucose (SMBG). Between-day glucose variability is measured by the standard deviation of FBG. LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], baseline LDL-C level \\[\\<100 mg/dL and \u2265100 mg/dL\\], and country), visit, treatment-by-visit interaction, and corresponding baseline dependent variable as the fixed effects, and participants as the random effect.", "timeFrame": "26 weeks and 52 weeks and 78 weeks"}, {"measure": "0300-hour Blood Glucose (BG) to Fasting Blood (FBG) Glucose Excursion", "description": "Results of a 0300-hour to pre-morning meal (FBG) excursion are presented (only SMBG profiles with both 0300 hours and the next day pre-morning measurements are included for the calculation of such excursion). LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], baseline LDL-C level \\[\\<100 mg/dL and \u2265100 mg/dL\\], and country), visit, treatment-by-visit interaction, and corresponding baseline dependent variable as the fixed effects and participants as the random effect.", "timeFrame": "26 weeks and 52 weeks and 78 weeks"}, {"measure": "9 Point Self-monitored Blood Glucose (SMBG)", "description": "9-point SMBG profiles were obtained over 2 days within the week prior to Weeks 0, 4, 12, 26, 39, 52, 65, and 78. SMBG measurements were taken at 9 time points: pre-morning meal, 2 hours post-morning meal, pre-midday meal, 2 hours post-midday meal, pre-evening meal, 2 hours post-evening meal, bedtime, at approximately 0300 hours, and the pre-morning meal the next day. LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], baseline LDL-C level \\[\\<100 mg/dL and \u2265100 mg/dL\\], and country), visit, treatment-by-visit interaction, and corresponding baseline dependent variable as the fixed effects and participants as the random effect.", "timeFrame": "26 weeks and 52 weeks and 78 weeks"}, {"measure": "Change From Baseline in Body Weight", "description": "LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], baseline LDL-C level \\[\\<100 mg/dL and \u2265100 mg/dL\\], and country), visit, treatment-by-visit interaction, and corresponding baseline dependent variable as the fixed effects, and participants as the random effect.", "timeFrame": "Baseline and 26 weeks and 52 weeks and 78 weeks"}, {"measure": "Basal, Bolus, and Total Insulin Dose", "description": "Basal insulin dose, short-acting bolus insulin dose (each meal and overall), and total insulin dose were calculated based on the dose during the last 7 days prior to the post-treatment visit or last 3 days prior to the randomization visit. LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], baseline LDL-C level \\[\\<100 mg/dL and \u2265100 mg/dL\\], and country), visit, treatment-by-visit interaction, and corresponding baseline dependent variable as the fixed effects and participants as the random effect.", "timeFrame": "26 weeks and 52 weeks and 78 weeks"}, {"measure": "Lipid Profile", "description": "Concentrations of cholesterol, high-density lipoprotein cholesterol (HDL-C), LDL-C, and triglycerides are summarized. LS means were calculated using MMRM, adjusting for stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, LDL-C \\[\\<100 mg/dL and \u2265100 mg/dL\\] except for the LDL-C outcome variable), visit, treatment, treatment-by-visit interaction, and baseline value of corresponding lipid outcome variable.", "timeFrame": "26 weeks and 52 weeks and 78 weeks"}, {"measure": "Percentage of Participants With Change in Anti-LY2605541 Antibodies", "description": "The percentage of participants with a treatment-emergent anti-LY2605541 antibody response (TEAR) is summarized. TEAR is defined as change from baseline to post-baseline in the anti-LY2605541 antibody level either from undetectable to detectable or from detectable to the value with at least 130% relative increase from baseline.", "timeFrame": "Baseline through 26 weeks and Baseline through 52 weeks and Baseline through 78 weeks"}, {"measure": "Insulin Treatment Satisfaction Questionnaire (ITSQ)", "description": "ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Inconvenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, and Insulin Delivery Device. Data presented are the transformed overall score on a scale of 0-100, where higher scores indicate better treatment satisfaction. LS means were calculated using an analysis of covariance (ANCOVA) model with treatment and stratification (baseline HbA1c \\[\u22648.5% or \\>8.5%\\] and country) as fixed effects and baseline value of the dependent variable as a covariate.", "timeFrame": "26 weeks"}, {"measure": "Low Blood Sugar Survey (LBSS)", "description": "LBSS (also referenced as Hypoglycemia Fear Survey - II \\[HFS-II\\]) is a 33-item questionnaire that measures 1) behaviors to avoid hypoglycemia and its negative consequences (15 items) and 2) worries about hypoglycemia and its negative consequences (18 items). Responses are made on a 5-point Likert scale where 0 = Never and 4 = Always. Total score is the sum of all items (range 0-132). Higher total scores reflect greater fear of hypoglycemia. LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\] and country), visit, treatment-by-visit interaction , and corresponding baseline dependent variable as the fixed effects and participants as the random effect.", "timeFrame": "26 weeks and 52 weeks and 78 weeks"}, {"measure": "European Quality of Life-5 Dimension (EQ-5D)", "description": "The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) using a 3-level scale of 1-3 (no problem, some problems, and extreme problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United States population-based algorithm. Scores range from -0.11 to 1.0, where a score of 1.0 indicates perfect health. LS means were calculated using ANCOVA, adjusting for treatment and stratification factors (baseline HbA1c \\[\u22648.5% or \\>8.5%\\] and country) as fixed effects and baseline EQ-5D score as a covariate.", "timeFrame": "26 weeks"}, {"measure": "Rapid Assessment of Physical Activity (RAPA)", "description": "The RAPA questionnaire assesses the level and intensity of physical activity of adult participants. It contains 2 subscales: RAPA 1 (Aerobic) and RAPA 2 (Strength and Flexibility). RAPA 1 contains 7 questions regarding the participant's amount and intensity of physical activity, allowing each participant's aerobic activity level to be categorized as sedentary, underactive, light activities, light activity, regular underactive, or active. RAPA 2 contains 2 questions regarding participants' physical activities that increase strength and improve flexibility. Each participant's strength and flexibility activity level is then categorized as neither strength nor flexibility (flex) activity, either strength or flex (not both), both strength and flex activity. The percentage of participants in each RAPA 1/2 category is presented and was calculated by dividing the number of participants in each RAPA 1/2 category by the total number of participants analyzed, then multiplying by 100.", "timeFrame": "26 weeks and 78 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have had diabetes mellitus for at least 1 year\n* Have an hemoglobin A1c (HbA1c) value less than 12% according to the central laboratory at screening\n* Have a body mass index (BMI) less than or equal to 35.0 kilograms per square meter (kg/m\\^2)\n* Have been treated for at least 90 days prior to screening with the following:\n\n  * Insulin detemir, insulin glargine, or human insulin isophane suspension (NPH) insulin in combination with premeal insulin,\n  * Self-mixed or premixed insulin regimens with any basal and bolus insulin combination administered at least twice daily, or\n  * Continuous SC insulin infusion therapy\n* This inclusion criterion applies to female participants:\n\n  * Are not breastfeeding\n  * Test negative for pregnancy at screening and randomization based on serum pregnancy tests\n  * Do not intend to become pregnant during the study\n  * Have practiced a reliable method of birth control (for example, use of oral contraceptives or levonorgestrel, diaphragms with contraceptive jelly, cervical caps with contraceptive jelly, condoms with contraceptive foam, intrauterine devices, partner with vasectomy, or abstinence) for at least 6 weeks prior to screening\n  * Agree to continue to use a reliable method of birth control during the study, as determined by the investigator (and for 2 weeks following the last dose of study drug)\n* Capable of and willing and desirous to do the following: adhere to a multiple daily injection regimen, inject insulin with a prefilled pen and perform Self-Monitored Blood Glucose (SMBG) and record keeping as required by this protocol, as determined by the investigator. Caregiver may be responsible for all of the above.\n\nExclusion Criteria:\n\n* Are using twice-daily insulin glargine having been inadequately controlled on once-daily dosed glargine prior to screening\n* Have excessive insulin resistance defined as having received a total daily dose of insulin greater than 1.5 units per kilogram (units/kg) at the time of randomization\n* Receiving any oral or injectable medication (other than metformin for treatment of polycystic ovarian disease) intended for the treatment of diabetes mellitus other than insulins in the 90 days prior to screening\n* Lipid-lowering medications:\n\n  * Are using niacin preparations as a lipid-lowering medication and/or bile acid sequestrants within 90 days prior to screening or are using lipid-lowering medication at a dose that has not been stable for greater than or equal to 90 days prior to screening\n  * If a participant has not been on a stable dose of lipid-lowering medication for greater than or equal to 90 days prior to screening, the site should wait to screen the participant. If the results of the screening laboratory tests require a change to the participant's current lipid-lowering medication or initiation of lipid-lowering medication, it is acceptable to change the lipid-lowering medication for the participant and to have the participant return greater than or equal to 90 days later to complete some of the screening procedures again\n* Have fasting hypertriglyceridemia (defined as greater than 4.5 millimoles per liter \\[mmol/L\\], greater than 400 milligrams per deciliter \\[mg/dL\\]) at screening, as determined by the central laboratory\n* Have had more than 1 episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia as determined by the investigator) within 6 months prior to entry into the study\n* Have had 2 or more emergency room visits or hospitalizations due to poor glucose control (hyperglycemia or diabetic ketoacidosis) in the past 6 months\n* Cardiovascular: have cardiac disease with functional status that is New York Heart Association Class III or IV (per New York Heart Association Cardiac Disease Classification)\n* Renal: Have a history of renal transplantation or are currently receiving renal dialysis or have serum creatinine greater than 2.5 mg/dL\n* Hepatic: Have obvious clinical signs or symptoms of liver disease (excluding non-alcoholic fatty liver disease \\[NAFLD\\]), acute or chronic hepatitis, non-alcoholic steatohepatitis (NASH), or elevated liver enzyme measurements as indicated below:\n\n  * Total bilirubin greater than or equal to 2 times the upper limit of normal (ULN) as defined by the central laboratory,\n  * Alanine aminotransferase (ALT)/(serum glutamic pyruvic transaminase (SGPT) greater than 2.5 times ULN as defined by the central laboratory, or\n  * Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) greater than 2.5 times ULN as defined by the central laboratory.\n* Malignancy: Have active or untreated malignancy, have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years, or are at an increased risk for developing cancer or a recurrence of cancer in the opinion of the investigator\n* Allergy: Have known hypersensitivity or allergy to any of the study insulins or their excipients\n* Hematologic: Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the HbA1c measurement\n* Glucocorticoid therapy: Receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy (excluding topical , intraocular, intranasal, and inhaled preparations) or have received such therapy within 8 weeks immediately before screening with the exception of replacement therapy for adrenal insufficiency\n* Diagnosed clinically significant diabetic autonomic neuropathy, in the opinion of the investigator\n* Have any other condition (including known drug or alcohol abuse or psychiatric disorder including eating disorder) that precludes the participant from following and completing the protocol", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", "affiliation": "Eli Lilly and Company", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Concord", "state": "California", "zip": "94520", "country": "United States", "geoPoint": {"lat": 37.97798, "lon": -122.03107}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Escondido", "state": "California", "zip": "92026", "country": "United States", "geoPoint": {"lat": 33.11921, "lon": -117.08642}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Greenbrae", "state": "California", "zip": "94904", "country": "United States", "geoPoint": {"lat": 37.94854, "lon": -122.5247}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Huntington Beach", "state": "California", "zip": "92648", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "San Mateo", "state": "California", "zip": "94401", "country": "United States", "geoPoint": {"lat": 37.56299, "lon": -122.32553}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Aurora", "state": "Colorado", "zip": "80010", "country": "United States", "geoPoint": {"lat": 39.72943, "lon": -104.83192}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Idaho Falls", "state": "Idaho", "zip": "83404", "country": "United States", "geoPoint": {"lat": 43.46658, "lon": -112.03414}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Las Vegas", "state": "Nevada", "zip": "89148", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Salt Lake City", "state": "Utah", "zip": "84102", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Renton", "state": "Washington", "zip": "98057", "country": "United States", "geoPoint": {"lat": 47.48288, "lon": -122.21707}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Spokane", "state": "Washington", "zip": "99202", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Graz", "zip": "8036", "country": "Austria", "geoPoint": {"lat": 47.06667, "lon": 15.45}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Vienna", "zip": "1130", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Bar Le Duc", "zip": "55000", "country": "France", "geoPoint": {"lat": 48.78333, "lon": 5.16667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Corbeil-Essonnes", "zip": "91100", "country": "France", "geoPoint": {"lat": 48.60603, "lon": 2.48757}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Montpellier", "zip": "34295", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Nantes", "zip": "44093", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Nice", "zip": "06002", "country": "France", "geoPoint": {"lat": 43.70313, "lon": 7.26608}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Saint Mande", "zip": "94160", "country": "France", "geoPoint": {"lat": 48.83864, "lon": 2.41579}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Toulouse", "zip": "31059", "country": "France", "geoPoint": {"lat": 43.60426, "lon": 1.44367}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Venissieux", "zip": "69200", "country": "France", "geoPoint": {"lat": 45.70254, "lon": 4.87147}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Berlin", "zip": "10409", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Eisenach", "zip": "99817", "country": "Germany", "geoPoint": {"lat": 50.9807, "lon": 10.31522}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Falkensee", "zip": "14612", "country": "Germany", "geoPoint": {"lat": 52.56014, "lon": 13.0927}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Hamburg", "zip": "22559", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Mainz", "zip": "55116", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Mayen", "zip": "56727", "country": "Germany", "geoPoint": {"lat": 50.32797, "lon": 7.22277}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "M\u00fcnster", "zip": "48153", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Neuwied", "zip": "56564", "country": "Germany", "geoPoint": {"lat": 50.4336, "lon": 7.47057}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Pohlheim", "zip": "35415", "country": "Germany"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Cagliari", "zip": "09100", "country": "Italy", "geoPoint": {"lat": 39.23054, "lon": 9.11917}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Catania", "zip": "95100", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Lecce", "zip": "73100", "country": "Italy", "geoPoint": {"lat": 40.35481, "lon": 18.17244}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Padova", "zip": "35128", "country": "Italy", "geoPoint": {"lat": 45.40797, "lon": 11.88586}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Perugia", "zip": "06100", "country": "Italy", "geoPoint": {"lat": 43.1122, "lon": 12.38878}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Ravenna", "zip": "48100", "country": "Italy", "geoPoint": {"lat": 44.41344, "lon": 12.20121}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Hokkaido", "zip": "060-0002", "country": "Japan", "geoPoint": {"lat": 43.41104, "lon": 142.88878}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Kanagawa", "zip": "235-0045", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Kumamoto", "zip": "862-0976", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69182}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Tokyo", "zip": "162-8666", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Guadalajara Jalisco", "zip": "04460", "country": "Mexico"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Guadalajara", "zip": "44150", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Monterrey", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Katowice", "zip": "40-057", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Lodz", "zip": "93-338", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Poznan", "zip": "61-655", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Warsaw", "zip": "01-192", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Arkhangelsk", "zip": "163045", "country": "Russian Federation", "geoPoint": {"lat": 64.5401, "lon": 40.5433}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Moscow", "zip": "119991", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Saint Petersburg", "zip": "193257", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}]}, "referencesModule": {"references": [{"pmid": "29167192", "type": "DERIVED", "citation": "Sanyal A, Cusi K, Hartman ML, Zhang S, Bastyr EJ 3rd, Bue-Valleskey JM, Chang AM, Haupt A, Jacober SJ, Konrad RJ, Zhang Q, Hoogwerf BJ. Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins. J Investig Med. 2018 Mar;66(3):661-668. doi: 10.1136/jim-2017-000609. Epub 2017 Nov 21."}, {"pmid": "28587667", "type": "DERIVED", "citation": "Orchard TJ, Cariou B, Connelly MA, Otvos JD, Zhang S, Antalis CJ, Ivanyi T, Hoogwerf BJ. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes. Cardiovasc Diabetol. 2017 Jun 6;16(1):73. doi: 10.1186/s12933-017-0555-1."}, {"pmid": "28417532", "type": "DERIVED", "citation": "Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, Haupt A. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab. 2017 Nov;19(11):1630-1634. doi: 10.1111/dom.12973. Epub 2017 Jun 22."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by subcutaneous (SC) injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "FG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "295"}, {"groupId": "FG001", "numSubjects": "160"}]}, {"type": "Received at Least 1 Dose of Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "294"}, {"groupId": "FG001", "numSubjects": "159"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "225"}, {"groupId": "FG001", "numSubjects": "132"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "70"}, {"groupId": "FG001", "numSubjects": "28"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "23"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Sponsor Decision", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All randomized participants.", "groups": [{"id": "BG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "BG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "295"}, {"groupId": "BG001", "value": "160"}, {"groupId": "BG002", "value": "455"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39.68", "spread": "12.93"}, {"groupId": "BG001", "value": "38.91", "spread": "14.10"}, {"groupId": "BG002", "value": "39.41", "spread": "13.34"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "157"}, {"groupId": "BG001", "value": "73"}, {"groupId": "BG002", "value": "230"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "138"}, {"groupId": "BG001", "value": "87"}, {"groupId": "BG002", "value": "225"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "49"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "153"}, {"groupId": "BG001", "value": "85"}, {"groupId": "BG002", "value": "238"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "109"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "168"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "9"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "63"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "94"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "5"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "221"}, {"groupId": "BG001", "value": "125"}, {"groupId": "BG002", "value": "346"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"title": "France", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "37"}]}]}, {"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "130"}]}]}, {"title": "Mexico", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "40"}]}]}, {"title": "Poland", "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "41"}]}]}, {"title": "Austria", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "11"}]}]}, {"title": "Russia", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "20"}]}]}, {"title": "Germany", "categories": [{"measurements": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "66"}]}]}, {"title": "Japan", "categories": [{"measurements": [{"groupId": "BG000", "value": "60"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "91"}]}]}, {"title": "Italy", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "19"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Hemoglobin A1c (HbA1c) at 26 Weeks", "description": "HbA1c is a test that measures a participant's average blood glucose level over a 2- to 3-month timeframe. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM), adjusting for treatment, stratification factors (baseline low-density lipoprotein cholesterol \\[LDL-C\\] \\[\\<100 milligrams per deciliter (mg/dL) and \u2265100 mg/dL\\] and country), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable HbA1c data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.06", "spread": "0.04"}, {"groupId": "OG001", "value": "7.43", "spread": "0.06"}]}]}]}, {"type": "SECONDARY", "title": "Hemoglobin A1c (HbA1c)", "description": "HbA1c is a test that measures a participant's average blood glucose level over a 2- to 3-month timeframe. LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline LDL-C \\[\\<100 mg/dL and \u2265100 mg/dL\\] and country), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable HbA1c data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "52 weeks and 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.30", "spread": "0.05"}, {"groupId": "OG001", "value": "7.55", "spread": "0.06"}]}]}, {"title": "Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.43", "spread": "0.05"}, {"groupId": "OG001", "value": "7.70", "spread": "0.07"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Hemoglobin A1c (HbA1c)", "description": "HbA1c is a test that measures a participant's average blood glucose level over a 2- to 3-month timeframe. LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline LDL-C \\[\\<100 mg/dL and \u2265100 mg/dL\\] and country), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable HbA1c data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "Baseline, 26 weeks, 52 weeks, 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.69", "spread": "0.04"}, {"groupId": "OG001", "value": "-0.33", "spread": "0.06"}]}]}, {"title": "Week 56", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.46", "spread": "0.05"}, {"groupId": "OG001", "value": "-0.21", "spread": "0.06"}]}]}, {"title": "Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.33", "spread": "0.05"}, {"groupId": "OG001", "value": "-0.05", "spread": "0.07"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Hemoglobin A1c (HbA1c) Less Than 7.0% or Less Than or Equal to 6.5% Using Last Observation Carried Forward (LOCF)", "description": "HbA1c is a test that measures a participant's average blood glucose level over a 2- to 3-month timeframe. The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, then multiplying by 100.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable HbA1c data. Missing endpoints were imputed with the LOCF method, using only post-baseline data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "26 weeks and 52 weeks and 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"title": "HbA1c \u22646.5%, Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "28.6"}, {"groupId": "OG001", "value": "13.7"}]}]}, {"title": "HbA1c \u22646.5%, Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.3"}, {"groupId": "OG001", "value": "13.1"}]}]}, {"title": "HbA1c \u22646.5%, Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.2"}, {"groupId": "OG001", "value": "13.1"}]}]}, {"title": "HbA1c <7.0%, Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.9"}, {"groupId": "OG001", "value": "27.5"}]}]}, {"title": "HbA1c <7.0%, Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "37.3"}, {"groupId": "OG001", "value": "28.1"}]}]}, {"title": "HbA1c <7.0%, Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "34.5"}, {"groupId": "OG001", "value": "22.9"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Participants With Hemoglobin A1c (HbA1c) Less Than 7.0% Without Nocturnal Hypoglycemia", "description": "Hypoglycemic episodes are defined as an event that is associated with reported signs and symptoms of hypoglycemia and/or a documented blood glucose concentration of \u226470 mg/dL (3.9 millimoles per liter \\[mmol/L\\]). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. The percentage of participants was calculated by dividing the number of participants with HbA1c \\<7.0% without nocturnal hypoglycemia by the total number of participants analyzed, then multiplying by 100.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable data. Missing endpoints were imputed with the LOCF method.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "26 weeks and 52 weeks and 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8"}, {"groupId": "OG001", "value": "2.0"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.1"}, {"groupId": "OG001", "value": "0.7"}]}]}, {"title": "Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0"}, {"groupId": "OG001", "value": "0.0"}]}]}]}, {"type": "SECONDARY", "title": "Total Hypoglycemia Rates (Adjusted by 30 Days)", "description": "Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of \u226470 mg/dL (3.9 mmol/L). Group mean rates of total hypoglycemia (per 30 days) are presented and were calculated from negative binomial regression models (number of episodes = treatment + baseline total hypoglycemia rate, with log \\[exposure in days/30\\] as an offset variable). Group mean is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "episodes/participant/30 days", "timeFrame": "Baseline through 26 weeks and Baseline through 52 weeks and Baseline through 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "293"}, {"groupId": "OG001", "value": "159"}]}], "classes": [{"title": "Baseline-Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.01", "spread": "0.44"}, {"groupId": "OG001", "value": "12.43", "spread": "0.55"}]}]}, {"title": "Baseline-Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "14.84", "spread": "0.42"}, {"groupId": "OG001", "value": "11.75", "spread": "0.55"}]}]}, {"title": "Baseline-Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "14.33", "spread": "0.42"}, {"groupId": "OG001", "value": "11.43", "spread": "0.55"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Total Hypoglycemia Events", "description": "Hypoglycemic events are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented BG concentrations of \u226470 mg/dL (3.9 mmol/L). The percentage of participants was calculated by dividing the number of participants with hypoglycemic episodes by the total number of participants analyzed, then multiplying by 100.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline through 26 weeks and Baseline through 52 weeks and Baseline through 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "294"}, {"groupId": "OG001", "value": "159"}]}], "classes": [{"title": "Baseline-Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "99.0"}, {"groupId": "OG001", "value": "96.9"}]}]}, {"title": "Baseline-Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "99.0"}, {"groupId": "OG001", "value": "96.9"}]}]}, {"title": "Baseline-Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "99.0"}, {"groupId": "OG001", "value": "96.9"}]}]}]}, {"type": "SECONDARY", "title": "Nocturnal Hypoglycemia Rates (Adjusted by 30 Days)", "description": "Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or a documented BG concentration of \u226470 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. Group mean rates of nocturnal hypoglycemia (per 30 days) are presented and were calculated from negative binomial regression models (number of episodes = treatment + baseline nocturnal hypoglycemia rate, with log \\[exposure in days/30\\] as an offset variable). Group mean is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "episodes/participant/30 days", "timeFrame": "Baseline through 26 weeks and Baseline through 52 weeks and Baseline through 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "293"}, {"groupId": "OG001", "value": "159"}]}], "classes": [{"title": "Baseline-Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.69", "spread": "0.12"}, {"groupId": "OG001", "value": "2.66", "spread": "0.19"}]}]}, {"title": "Baseline-Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.63", "spread": "0.11"}, {"groupId": "OG001", "value": "2.45", "spread": "0.19"}]}]}, {"title": "Baseline-Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.58", "spread": "0.11"}, {"groupId": "OG001", "value": "2.28", "spread": "0.17"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Nocturnal Hypoglycemic Events", "description": "Hypoglycemic episodes are defined as an event that is associated with reported signs and symptoms of hypoglycemia and/or a BG concentration of \u226470 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. The percentage of participants was calculated by dividing the number of participants with nocturnal hypoglycemic episodes by the total number of participants analyzed, then multiplying by 100.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline through 26 weeks and Baseline through 52 weeks and Baseline through 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "294"}, {"groupId": "OG001", "value": "159"}]}], "classes": [{"title": "Baseline-Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "87.4"}, {"groupId": "OG001", "value": "90.6"}]}]}, {"title": "Baseline-Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "91.5"}, {"groupId": "OG001", "value": "91.8"}]}]}, {"title": "Baseline-Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "93.5"}, {"groupId": "OG001", "value": "92.5"}]}]}]}, {"type": "SECONDARY", "title": "Fasting Serum Glucose (FSG) by Laboratory Measurement", "description": "LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], baseline LDL-C level \\[\\<100 mg/dL and \u2265100 mg/dL\\], and country), visit, treatment-by-visit interaction, and corresponding baseline dependent variable as the fixed effects, and participants as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable FSG data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "26 weeks and 52 weeks and 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "285"}, {"groupId": "OG001", "value": "152"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "138.22", "spread": "3.80"}, {"groupId": "OG001", "value": "160.35", "spread": "5.06"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "146.55", "spread": "4.42"}, {"groupId": "OG001", "value": "164.28", "spread": "5.72"}]}]}, {"title": "Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "144.64", "spread": "4.53"}, {"groupId": "OG001", "value": "164.78", "spread": "5.81"}]}]}]}, {"type": "SECONDARY", "title": "Fasting Blood Glucose (FBG) Intra-participant Variability", "description": "FBG was measured by self-monitored blood glucose (SMBG). Between-day glucose variability is measured by the standard deviation of FBG. LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], baseline LDL-C level \\[\\<100 mg/dL and \u2265100 mg/dL\\], and country), visit, treatment-by-visit interaction, and corresponding baseline dependent variable as the fixed effects, and participants as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable FBG data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "26 weeks and 52 weeks and 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "282"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "52.49", "spread": "1.79"}, {"groupId": "OG001", "value": "59.25", "spread": "2.43"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "53.44", "spread": "1.85"}, {"groupId": "OG001", "value": "58.15", "spread": "2.43"}]}]}, {"title": "Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "54.87", "spread": "2.20"}, {"groupId": "OG001", "value": "60.66", "spread": "2.79"}]}]}]}, {"type": "SECONDARY", "title": "0300-hour Blood Glucose (BG) to Fasting Blood (FBG) Glucose Excursion", "description": "Results of a 0300-hour to pre-morning meal (FBG) excursion are presented (only SMBG profiles with both 0300 hours and the next day pre-morning measurements are included for the calculation of such excursion). LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], baseline LDL-C level \\[\\<100 mg/dL and \u2265100 mg/dL\\], and country), visit, treatment-by-visit interaction, and corresponding baseline dependent variable as the fixed effects and participants as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable SMBG data at baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "26 weeks and 52 weeks and 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "112"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.92", "spread": "6.24"}, {"groupId": "OG001", "value": "-14.08", "spread": "8.75"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.15", "spread": "6.91"}, {"groupId": "OG001", "value": "-9.02", "spread": "9.58"}]}]}, {"title": "Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.82", "spread": "8.25"}, {"groupId": "OG001", "value": "-28.94", "spread": "10.50"}]}]}]}, {"type": "SECONDARY", "title": "9 Point Self-monitored Blood Glucose (SMBG)", "description": "9-point SMBG profiles were obtained over 2 days within the week prior to Weeks 0, 4, 12, 26, 39, 52, 65, and 78. SMBG measurements were taken at 9 time points: pre-morning meal, 2 hours post-morning meal, pre-midday meal, 2 hours post-midday meal, pre-evening meal, 2 hours post-evening meal, bedtime, at approximately 0300 hours, and the pre-morning meal the next day. LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], baseline LDL-C level \\[\\<100 mg/dL and \u2265100 mg/dL\\], and country), visit, treatment-by-visit interaction, and corresponding baseline dependent variable as the fixed effects and participants as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable SMBG data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "26 weeks and 52 weeks and 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "271"}, {"groupId": "OG001", "value": "143"}]}], "classes": [{"title": "Pre-morning meal, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "271"}, {"groupId": "OG001", "value": "143"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "158.58", "spread": "3.82"}, {"groupId": "OG001", "value": "144.40", "spread": "5.20"}]}]}, {"title": "Pre-morning meal, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "271"}, {"groupId": "OG001", "value": "143"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "160.89", "spread": "4.13"}, {"groupId": "OG001", "value": "152.55", "spread": "5.38"}]}]}, {"title": "Pre-morning meal, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "271"}, {"groupId": "OG001", "value": "143"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "163.09", "spread": "4.66"}, {"groupId": "OG001", "value": "153.38", "spread": "5.99"}]}]}, {"title": "2 hours post-morning meal, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "245"}, {"groupId": "OG001", "value": "125"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "172.39", "spread": "4.59"}, {"groupId": "OG001", "value": "165.53", "spread": "6.44"}]}]}, {"title": "2 hours post-morning meal, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "245"}, {"groupId": "OG001", "value": "125"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "176.32", "spread": "5.61"}, {"groupId": "OG001", "value": "168.38", "spread": "7.47"}]}]}, {"title": "2 hours post-morning meal, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "245"}, {"groupId": "OG001", "value": "125"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "183.64", "spread": "6.23"}, {"groupId": "OG001", "value": "190.54", "spread": "7.91"}]}]}, {"title": "Pre-midday meal, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "264"}, {"groupId": "OG001", "value": "140"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "136.21", "spread": "3.92"}, {"groupId": "OG001", "value": "153.12", "spread": "5.33"}]}]}, {"title": "Pre-midday meal, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "264"}, {"groupId": "OG001", "value": "140"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "142.82", "spread": "4.27"}, {"groupId": "OG001", "value": "149.78", "spread": "5.66"}]}]}, {"title": "Pre-midday meal, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "264"}, {"groupId": "OG001", "value": "140"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "150.83", "spread": "4.90"}, {"groupId": "OG001", "value": "154.56", "spread": "6.33"}]}]}, {"title": "2 hours post-midday meal, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "244"}, {"groupId": "OG001", "value": "122"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "157.17", "spread": "4.78"}, {"groupId": "OG001", "value": "164.75", "spread": "6.69"}]}]}, {"title": "2 hours post-midday meal, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "244"}, {"groupId": "OG001", "value": "122"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "159.59", "spread": "5.11"}, {"groupId": "OG001", "value": "168.83", "spread": "6.94"}]}]}, {"title": "2 hours post-midday meal, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "244"}, {"groupId": "OG001", "value": "122"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "154.46", "spread": "5.76"}, {"groupId": "OG001", "value": "175.52", "spread": "7.51"}]}]}, {"title": "Pre-evening meal, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "143"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "153.20", "spread": "4.29"}, {"groupId": "OG001", "value": "168.08", "spread": "5.75"}]}]}, {"title": "Pre-evening meal, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "143"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "153.01", "spread": "5.17"}, {"groupId": "OG001", "value": "183.18", "spread": "6.81"}]}]}, {"title": "Pre-evening meal, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "143"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "149.89", "spread": "4.92"}, {"groupId": "OG001", "value": "174.50", "spread": "6.17"}]}]}, {"title": "2 hours post-evening meal, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "232"}, {"groupId": "OG001", "value": "126"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "149.74", "spread": "5.17"}, {"groupId": "OG001", "value": "191.99", "spread": "7.20"}]}]}, {"title": "2 hours post-evening meal, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "232"}, {"groupId": "OG001", "value": "126"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "157.81", "spread": "6.79"}, {"groupId": "OG001", "value": "198.10", "spread": "9.06"}]}]}, {"title": "2 hours post-evening meal, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "232"}, {"groupId": "OG001", "value": "126"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "163.27", "spread": "6.07"}, {"groupId": "OG001", "value": "189.43", "spread": "7.75"}]}]}, {"title": "Bedtime, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "250"}, {"groupId": "OG001", "value": "137"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "151.66", "spread": "4.15"}, {"groupId": "OG001", "value": "176.17", "spread": "5.63"}]}]}, {"title": "Bedtime, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "250"}, {"groupId": "OG001", "value": "137"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "167.35", "spread": "5.33"}, {"groupId": "OG001", "value": "182.08", "spread": "7.11"}]}]}, {"title": "Bedtime, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "250"}, {"groupId": "OG001", "value": "137"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "165.63", "spread": "5.37"}, {"groupId": "OG001", "value": "185.45", "spread": "6.74"}]}]}, {"title": "0300 hours, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "159.73", "spread": "5.30"}, {"groupId": "OG001", "value": "163.18", "spread": "7.50"}]}]}, {"title": "0300 hours, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "157.52", "spread": "6.06"}, {"groupId": "OG001", "value": "148.26", "spread": "8.36"}]}]}, {"title": "0300 hours, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "165.82", "spread": "7.19"}, {"groupId": "OG001", "value": "170.35", "spread": "9.02"}]}]}, {"title": "Pre-morning meal next day, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "260"}, {"groupId": "OG001", "value": "138"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "149.94", "spread": "3.74"}, {"groupId": "OG001", "value": "143.89", "spread": "5.10"}]}]}, {"title": "Pre-morning meal next day, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "260"}, {"groupId": "OG001", "value": "138"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "155.79", "spread": "4.24"}, {"groupId": "OG001", "value": "145.55", "spread": "5.59"}]}]}, {"title": "Pre-morning meal next day, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "260"}, {"groupId": "OG001", "value": "138"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "156.87", "spread": "4.80"}, {"groupId": "OG001", "value": "152.63", "spread": "6.11"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight", "description": "LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], baseline LDL-C level \\[\\<100 mg/dL and \u2265100 mg/dL\\], and country), visit, treatment-by-visit interaction, and corresponding baseline dependent variable as the fixed effects, and participants as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable body weight data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kilograms (kg)", "timeFrame": "Baseline and 26 weeks and 52 weeks and 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}, {"groupId": "OG001", "value": "154"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.17", "spread": "0.20"}, {"groupId": "OG001", "value": "0.71", "spread": "0.27"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.22", "spread": "0.25"}, {"groupId": "OG001", "value": "1.00", "spread": "0.33"}]}]}, {"title": "Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.93", "spread": "0.28"}, {"groupId": "OG001", "value": "1.04", "spread": "0.37"}]}]}]}, {"type": "SECONDARY", "title": "Basal, Bolus, and Total Insulin Dose", "description": "Basal insulin dose, short-acting bolus insulin dose (each meal and overall), and total insulin dose were calculated based on the dose during the last 7 days prior to the post-treatment visit or last 3 days prior to the randomization visit. LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], baseline LDL-C level \\[\\<100 mg/dL and \u2265100 mg/dL\\], and country), visit, treatment-by-visit interaction, and corresponding baseline dependent variable as the fixed effects and participants as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable insulin dose data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units/kg/day", "timeFrame": "26 weeks and 52 weeks and 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "282"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"title": "Basal Insulin, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "239"}, {"groupId": "OG001", "value": "127"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.40", "spread": "0.01"}, {"groupId": "OG001", "value": "0.34", "spread": "0.01"}]}]}, {"title": "Basal Insulin, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "239"}, {"groupId": "OG001", "value": "127"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.40", "spread": "0.01"}, {"groupId": "OG001", "value": "0.34", "spread": "0.01"}]}]}, {"title": "Basal Insulin, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "239"}, {"groupId": "OG001", "value": "127"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.41", "spread": "0.01"}, {"groupId": "OG001", "value": "0.35", "spread": "0.01"}]}]}, {"title": "Bolus Insulin, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "153"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.37", "spread": "0.01"}, {"groupId": "OG001", "value": "0.46", "spread": "0.02"}]}]}, {"title": "Bolus Insulin, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "153"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.38", "spread": "0.01"}, {"groupId": "OG001", "value": "0.47", "spread": "0.02"}]}]}, {"title": "Bolus Insulin, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "153"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.37", "spread": "0.02"}, {"groupId": "OG001", "value": "0.48", "spread": "0.02"}]}]}, {"title": "Total Insulin, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "282"}, {"groupId": "OG001", "value": "156"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.73", "spread": "0.02"}, {"groupId": "OG001", "value": "0.78", "spread": "0.02"}]}]}, {"title": "Total Insulin, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "282"}, {"groupId": "OG001", "value": "156"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.74", "spread": "0.02"}, {"groupId": "OG001", "value": "0.79", "spread": "0.03"}]}]}, {"title": "Total Insulin, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "282"}, {"groupId": "OG001", "value": "156"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.75", "spread": "0.02"}, {"groupId": "OG001", "value": "0.80", "spread": "0.03"}]}]}]}, {"type": "SECONDARY", "title": "Lipid Profile", "description": "Concentrations of cholesterol, high-density lipoprotein cholesterol (HDL-C), LDL-C, and triglycerides are summarized. LS means were calculated using MMRM, adjusting for stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, LDL-C \\[\\<100 mg/dL and \u2265100 mg/dL\\] except for the LDL-C outcome variable), visit, treatment, treatment-by-visit interaction, and baseline value of corresponding lipid outcome variable.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable lipid data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "26 weeks and 52 weeks and 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "288"}, {"groupId": "OG001", "value": "152"}]}], "classes": [{"title": "Cholesterol, Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "191.86", "spread": "1.63"}, {"groupId": "OG001", "value": "187.93", "spread": "2.19"}]}]}, {"title": "Cholesterol, Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "190.72", "spread": "1.59"}, {"groupId": "OG001", "value": "188.65", "spread": "2.10"}]}]}, {"title": "Cholesterol, Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "191.78", "spread": "1.86"}, {"groupId": "OG001", "value": "190.06", "spread": "2.39"}]}]}, {"title": "HDL-C, Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.87", "spread": "0.59"}, {"groupId": "OG001", "value": "62.75", "spread": "0.80"}]}]}, {"title": "HDL-C, Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.01", "spread": "0.56"}, {"groupId": "OG001", "value": "61.46", "spread": "0.74"}]}]}, {"title": "HDL-C, Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "60.77", "spread": "0.66"}, {"groupId": "OG001", "value": "61.97", "spread": "0.85"}]}]}, {"title": "LDL-C, Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "108.85", "spread": "1.33"}, {"groupId": "OG001", "value": "108.31", "spread": "1.79"}]}]}, {"title": "LDL-C, Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "109.40", "spread": "1.39"}, {"groupId": "OG001", "value": "109.74", "spread": "1.84"}]}]}, {"title": "LDL-C, Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "109.62", "spread": "1.62"}, {"groupId": "OG001", "value": "110.35", "spread": "2.09"}]}]}, {"title": "Triglycerides, Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "109.64", "spread": "3.89"}, {"groupId": "OG001", "value": "85.35", "spread": "5.24"}]}]}, {"title": "Triglycerides, Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "105.17", "spread": "3.64"}, {"groupId": "OG001", "value": "87.94", "spread": "4.80"}]}]}, {"title": "Triglycerides, Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "110.80", "spread": "4.78"}, {"groupId": "OG001", "value": "88.96", "spread": "6.14"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Change in Anti-LY2605541 Antibodies", "description": "The percentage of participants with a treatment-emergent anti-LY2605541 antibody response (TEAR) is summarized. TEAR is defined as change from baseline to post-baseline in the anti-LY2605541 antibody level either from undetectable to detectable or from detectable to the value with at least 130% relative increase from baseline.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable anti-LY2605541 antibody data at baseline and post-baseline. Missing endpoints were imputed with the LOCF method.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline through 26 weeks and Baseline through 52 weeks and Baseline through 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "288"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"title": "Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "288"}, {"groupId": "OG001", "value": "152"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "30.6"}, {"groupId": "OG001", "value": "15.8"}]}]}, {"title": "Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "288"}, {"groupId": "OG001", "value": "152"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "29.9"}, {"groupId": "OG001", "value": "17.1"}]}]}, {"title": "Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "288"}, {"groupId": "OG001", "value": "153"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "26.4"}, {"groupId": "OG001", "value": "13.1"}]}]}]}, {"type": "SECONDARY", "title": "Insulin Treatment Satisfaction Questionnaire (ITSQ)", "description": "ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Inconvenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, and Insulin Delivery Device. Data presented are the transformed overall score on a scale of 0-100, where higher scores indicate better treatment satisfaction. LS means were calculated using an analysis of covariance (ANCOVA) model with treatment and stratification (baseline HbA1c \\[\u22648.5% or \\>8.5%\\] and country) as fixed effects and baseline value of the dependent variable as a covariate.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable ITSQ data at both baseline and post-baseline. Missing endpoints were imputed with the LOCF method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "273"}, {"groupId": "OG001", "value": "149"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "72.43", "spread": "0.69"}, {"groupId": "OG001", "value": "73.91", "spread": "0.94"}]}]}]}, {"type": "SECONDARY", "title": "Low Blood Sugar Survey (LBSS)", "description": "LBSS (also referenced as Hypoglycemia Fear Survey - II \\[HFS-II\\]) is a 33-item questionnaire that measures 1) behaviors to avoid hypoglycemia and its negative consequences (15 items) and 2) worries about hypoglycemia and its negative consequences (18 items). Responses are made on a 5-point Likert scale where 0 = Never and 4 = Always. Total score is the sum of all items (range 0-132). Higher total scores reflect greater fear of hypoglycemia. LS means were calculated using MMRM, adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\] and country), visit, treatment-by-visit interaction , and corresponding baseline dependent variable as the fixed effects and participants as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable LBSS data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "26 weeks and 52 weeks and 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}, {"groupId": "OG001", "value": "151"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "28.09", "spread": "0.70"}, {"groupId": "OG001", "value": "27.09", "spread": "0.95"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "27.76", "spread": "0.77"}, {"groupId": "OG001", "value": "27.00", "spread": "1.01"}]}]}, {"title": "Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "27.68", "spread": "0.91"}, {"groupId": "OG001", "value": "27.14", "spread": "1.18"}]}]}]}, {"type": "SECONDARY", "title": "European Quality of Life-5 Dimension (EQ-5D)", "description": "The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) using a 3-level scale of 1-3 (no problem, some problems, and extreme problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United States population-based algorithm. Scores range from -0.11 to 1.0, where a score of 1.0 indicates perfect health. LS means were calculated using ANCOVA, adjusting for treatment and stratification factors (baseline HbA1c \\[\u22648.5% or \\>8.5%\\] and country) as fixed effects and baseline EQ-5D score as a covariate.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable EQ-5D data at both baseline and post-baseline. Missing endpoints were imputed with the LOCF method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "277"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.92", "spread": "0.01"}, {"groupId": "OG001", "value": "0.91", "spread": "0.01"}]}]}]}, {"type": "SECONDARY", "title": "Rapid Assessment of Physical Activity (RAPA)", "description": "The RAPA questionnaire assesses the level and intensity of physical activity of adult participants. It contains 2 subscales: RAPA 1 (Aerobic) and RAPA 2 (Strength and Flexibility). RAPA 1 contains 7 questions regarding the participant's amount and intensity of physical activity, allowing each participant's aerobic activity level to be categorized as sedentary, underactive, light activities, light activity, regular underactive, or active. RAPA 2 contains 2 questions regarding participants' physical activities that increase strength and improve flexibility. Each participant's strength and flexibility activity level is then categorized as neither strength nor flexibility (flex) activity, either strength or flex (not both), both strength and flex activity. The percentage of participants in each RAPA 1/2 category is presented and was calculated by dividing the number of participants in each RAPA 1/2 category by the total number of participants analyzed, then multiplying by 100.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable RAPA data. Missing endpoints were imputed with the LOCF method, using only post-baseline data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "26 weeks and 78 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}, {"id": "OG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"title": "RAPA 1, Sedentary, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0"}, {"groupId": "OG001", "value": "0.0"}]}]}, {"title": "RAPA 1, Sedentary, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3"}, {"groupId": "OG001", "value": "0.0"}]}]}, {"title": "RAPA 1, Underactive, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.1"}, {"groupId": "OG001", "value": "3.5"}]}]}, {"title": "RAPA 1, Underactive, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8"}, {"groupId": "OG001", "value": "2.0"}]}]}, {"title": "RAPA 1, Light activity, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.3"}, {"groupId": "OG001", "value": "10.5"}]}]}, {"title": "RAPA 1, Light activity, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.5"}, {"groupId": "OG001", "value": "13.7"}]}]}, {"title": "RAPA 1, Regular underactive, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "24.5"}, {"groupId": "OG001", "value": "29.8"}]}]}, {"title": "RAPA 1, Regular underactive, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "31.3"}, {"groupId": "OG001", "value": "29.4"}]}]}, {"title": "RAPA 1, Active, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "58.2"}, {"groupId": "OG001", "value": "56.1"}]}]}, {"title": "RAPA 1, Active, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "56.3"}, {"groupId": "OG001", "value": "54.9"}]}]}, {"title": "RAPA 2, Neither strength/flex, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "35.7"}, {"groupId": "OG001", "value": "43.9"}]}]}, {"title": "RAPA 2, Neither strength/flex, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "37.0"}, {"groupId": "OG001", "value": "47.1"}]}]}, {"title": "RAPA 2, Either strength/flex, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "30.6"}, {"groupId": "OG001", "value": "35.1"}]}]}, {"title": "RAPA 2, Either strength/flex, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "33.3"}, {"groupId": "OG001", "value": "29.4"}]}]}, {"title": "RAPA 2, Both strength/flex, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "33.7"}, {"groupId": "OG001", "value": "21.1"}]}]}, {"title": "RAPA 2, Both strength/flex, Week 78", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "29.6"}, {"groupId": "OG001", "value": "23.5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "eventGroups": [{"id": "EG000", "title": "LY2605541 + Insulin Lispro", "description": "LY2605541 titrated based on blood glucose readings, administered by subcutaneous (SC) injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered subcutaneously via pen device at meal times for 78 weeks.", "seriousNumAffected": 67, "seriousNumAtRisk": 294, "otherNumAffected": 256, "otherNumAtRisk": 294}, {"id": "EG001", "title": "Glargine + Insulin Lispro", "description": "Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.", "seriousNumAffected": 25, "seriousNumAtRisk": 159, "otherNumAffected": 112, "otherNumAtRisk": 159}], "seriousEvents": [{"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 4, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Sudden hearing loss", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Tympanic membrane perforation", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Faeces pale", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Impaired gastric emptying", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Small intestinal perforation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Anaphylactic shock", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Abscess limb", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Diabetic gangrene", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Infectious mononucleosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 2, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Post procedural sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Pseudomonas infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Staphylococcal sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Alcohol poisoning", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Clavicle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Incorrect dose administered", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Intentional overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 73, "numAffected": 45, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 20, "numAffected": 13, "numAtRisk": 159}]}, {"term": "Hyponatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Metabolic disorder", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Intervertebral disc degeneration", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Lumbar spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Muscle contracture", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Spondylolisthesis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Acute myeloid leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Benign bone neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Cervix carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}]}, {"term": "Fibroadenoma of breast", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 2, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}]}, {"term": "Complicated migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Hypoglycaemic coma", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Adjustment disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Urinary incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Cervical polyp", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}]}, {"term": "Menorrhagia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}]}, {"term": "Acute respiratory distress syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Skin ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 2, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Hysterectomy", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}]}, {"term": "Toe amputation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Intermittent claudication", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Peripheral artery stenosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 13, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 159}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 11, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 159}]}, {"term": "Cystitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 9, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 159}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 9, "numAffected": 8, "numAtRisk": 159}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 159}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 32, "numAffected": 25, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 14, "numAffected": 14, "numAtRisk": 159}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 152, "numAffected": 92, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 61, "numAffected": 38, "numAtRisk": 159}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 13, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 9, "numAffected": 7, "numAtRisk": 159}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 22, "numAffected": 13, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 17, "numAffected": 12, "numAtRisk": 159}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 15, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 14, "numAffected": 8, "numAtRisk": 159}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 12, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 159}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 15, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 159}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 27, "numAffected": 18, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 13, "numAffected": 10, "numAtRisk": 159}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 159}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 9, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 159}]}, {"term": "Lipodystrophy acquired", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 17, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}, {"term": "Lipohypertrophy", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 66, "numAffected": 45, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 10, "numAtRisk": 294}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Chief Medical Officer", "organization": "Eli Lilly and Company", "phone": "800-545-5979"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003922", "term": "Diabetes Mellitus, Type 1"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000001327", "term": "Autoimmune Diseases"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7117", "name": "Diabetes Mellitus, Type 1", "asFound": "Diabetes Mellitus, Type 1", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M4629", "name": "Autoimmune Diseases", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000061268", "term": "Insulin Lispro"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M29802", "name": "Insulin Lispro", "asFound": "AUC", "relevance": "HIGH"}, {"id": "M347", "name": "Insulin Glargine", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}